Wikisage, the free encyclopedia of the second generation, is digital heritage
Levetiracetam: Difference between revisions
Jump to navigation
Jump to search
m (dutch todo) |
m (→Links) |
||
| Line 3: | Line 3: | ||
[http://www.fda.gov/downloads/Drugs/DrugSafety/UCM312880.pdf Medication guide FDA] | [http://www.fda.gov/downloads/Drugs/DrugSafety/UCM312880.pdf Medication guide FDA] | ||
==Links== | ==Links== | ||
In mioclonic astatic epilepsy should be used with caution in children<ref>Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. BMC paeditrics</ref> | |||
===ATC=== | ===ATC=== | ||
{| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | {| style="background:Ivory; color:black" border=1 cellspacing=1 cellpadding=5 | ||
Revision as of 00:23, 30 March 2016
(S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat epilepsy. It is the S-enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam.
Extended release
Links
In mioclonic astatic epilepsy should be used with caution in children[1]
ATC
Trinka E., et al 2015 Pharmacotherapy for Status Epilepticus Drugs 75:1499
Safraski J.-P.2015
Jackson J.-L. et al.2015
- ↑ Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. BMC paeditrics
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AX14&showdescription=yes